|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,398,000 |
Market
Cap: |
299.62(M) |
Last
Volume: |
676,008 |
Avg
Vol: |
695,089 |
52
Week Range: |
$3.38 - $6.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 803 |
Guru Rank Value : 1 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
121,098 |
121,098 |
148,134 |
388,157 |
Total Sell Value |
$513,345 |
$513,345 |
$684,141 |
$2,735,436 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
10 |
10 |
14 |
33 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Polymeropoulos Mihael Hristos |
President and CEO |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
1,041,848 |
|
- |
|
Reverberi Gian Piero |
SVP & Chief Commercial Officer |
|
2017-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
50,000 |
|
- |
|
Kelly James Patrick |
SVP, CFO & Treasurer |
|
2017-01-03 |
4 |
S |
$15.51 |
$169,013 |
D/D |
(10,895) |
69,721 |
|
- |
|
Kelly James Patrick |
SVP, CFO & Treasurer |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,844 |
80,616 |
|
- |
|
Reverberi Gian Piero |
SVP & Chief Commercial Officer |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Baroldi Paolo |
SVP & Chief Medical Officer |
|
2017-01-03 |
4 |
S |
$15.51 |
$252,776 |
D/D |
(16,300) |
54,365 |
|
- |
|
Baroldi Paolo |
SVP & Chief Medical Officer |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
70,665 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2017-01-03 |
4 |
S |
$15.51 |
$169,090 |
D/D |
(10,900) |
9,100 |
|
- |
|
Gulino Richard L. |
SVP, General Counsel & Sec. |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2017-01-03 |
4 |
S |
$15.48 |
$361,242 |
D/D |
(23,330) |
850,848 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2017-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
874,178 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2016-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
9,000 |
830,178 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2016-09-23 |
4 |
S |
$16.71 |
$13,023,056 |
I/I |
(779,497) |
693,171 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2016-09-22 |
4 |
S |
$16.24 |
$5,536,914 |
I/I |
(340,964) |
850,778 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2016-09-19 |
4 |
S |
$15.53 |
$713,279 |
I/I |
(45,811) |
919,718 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2016-09-16 |
4 |
S |
$15.62 |
$4,691,510 |
I/I |
(300,372) |
956,762 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2016-09-15 |
4 |
S |
$15.76 |
$3,177,831 |
I/I |
(201,703) |
1,044,620 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2016-01-04 |
4 |
S |
$8.96 |
$191,323 |
D/D |
(21,353) |
839,178 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2016-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
43,750 |
860,531 |
|
- |
|
Baroldi Paolo |
SVP & Chief Medical Officer |
|
2016-01-04 |
4 |
S |
$8.96 |
$110,925 |
D/D |
(12,380) |
40,665 |
|
- |
|
Baroldi Paolo |
SVP & Chief Medical Officer |
|
2016-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,500 |
53,045 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEO |
|
2015-12-28 |
5 |
GD |
$0.00 |
$0 |
D/D |
15,000 |
801,781 |
|
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2015-12-16 |
4 |
B |
$8.97 |
$100,156 |
I/I |
11,170 |
1,103,617 |
1.5 |
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2015-12-11 |
4 |
B |
$8.61 |
$2,779,573 |
I/I |
322,872 |
1,100,378 |
1.5 |
- |
|
Deerfield Special Situations Fund, L.p. |
Possible Member of 10% Group |
|
2015-12-10 |
4 |
B |
$8.59 |
$885,736 |
I/I |
103,110 |
1,006,744 |
1.5 |
- |
|
272 Records found
|
|
Page 10 of 11 |
|
|